Roumen Balabanov to Natalizumab
This is a "connection" page, showing publications Roumen Balabanov has written about Natalizumab.
Connection Strength
0.326
-
Outcomes of natalizumab treatment within 3?years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. BMC Neurol. 2019 Jun 08; 19(1):116.
Score: 0.164
-
Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol. 2019 May; 6(5):923-931.
Score: 0.162